1. Cbl-b inhibition promotes less differentiated phenotypes of T cells with enhanced cytokine production.
- Author
-
Wang J, Han X, Hao Y, Chen S, Pang B, Zou L, Han X, Wang W, Liu L, Shen M, and Jin A
- Subjects
- Humans, Phospholipase C gamma metabolism, ZAP-70 Protein-Tyrosine Kinase metabolism, Phosphorylation drug effects, Immunotherapy, Adoptive methods, Phenotype, Cell Survival drug effects, Proto-Oncogene Proteins c-cbl metabolism, Lymphocyte Activation drug effects, Lymphocyte Activation immunology, T-Lymphocytes immunology, T-Lymphocytes drug effects, T-Lymphocytes metabolism, Cytokines metabolism, Adaptor Proteins, Signal Transducing metabolism, Receptors, Antigen, T-Cell metabolism, Receptors, Antigen, T-Cell immunology, Cell Differentiation drug effects, Cell Differentiation immunology, Cell Proliferation drug effects, Signal Transduction drug effects
- Abstract
For adoptive therapy with T cell receptor engineered T (TCR-T) cells, the quantity and quality of the final cell product directly affect their anti-tumor efficacy. The post-transfer efficacy window of TCR-T cells is keen to optimizing attempts during the manufacturing process. Cbl-b is a E3 ubiquitin ligase previously shown with critical negative impact in T cell functions. This study investigated whether strategic inclusion of a commercially available small inhibitor targeting Cbl-b (Cbl-b-IN-1) prior to T cell activation could enhance the quality of the final TCR-T cell product. Examination with both PBMCs and TCR-T cells revealed that Cbl-b-IN-1 treatment promoted TCR expression efficiency, T cell proliferation potential and, specifically, cell survival capability post antigenic stimulation. Cbl-b-IN-1 exposure facilitated T cells in maintaining less differentiated states with enhanced cytokine production. Further, we found that Cbl-b-IN-1 effectively augmented the activation of TCR signaling, shown by increased phosphorylation levels of Zeta-chain-associated protein kinase 70 (ZAP70) and phospholipase c-γ1 (PLCγ1). In conclusion, our results evidence that the inclusion of Cbl-b inhibitor immediately prior to TCR-T cell activation may enhance their proliferation, survival, and function potentials, presenting an applicable optimization strategy for immunotherapy with adoptive cell transfer., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF